Pharmacological Activity of Bioactive Compounds of Epimedium Sagittatum: Novel Antidepressant Mechanisms and Behavioral Perspectives

Depression remains a leading cause of disability worldwide, with conventional antidepressants often exhibiting limited efficacy and significant side effects. Epimedium sagittatum (Family Berberidaceae), a traditional Chinese medicinal herb, has demonstrated promising antidepressant-like effects in preclinical studies. This comprehensive review synthesizes recent literature on the pharmacological actions of E. sagittatum and its bioactive compounds, particularly icariin, icaritin, and their metabolites, with emphasis on novel antidepressant mechanisms and behavioral outcomes. Multiple signaling pathways contribute to the antidepressant effects, including modulation of monoamine neurotransmitter systems, inhibition of neuroinflammation via HMGB1-RAGE signaling, enhancement of neuroplasticity through BDNF-TrkB pathways, regulation of oxidative stress, and mitigation of corticosterone-induced apoptosis through MAPK inhibition. Behavioral studies utilizing chronic unpredictable mild stress (CUMS), forced swim test (FST), and tail suspension test (TST) models have consistently demonstrated the efficacy of E. sagittatum extracts and isolated compounds. This review critically examines the chemical composition, extraction methodologies, pharmacokinetic properties, molecular mechanisms, and future perspectives for clinical development of E. sagittatum-based antidepressant therapeutics.